University Hospital Southampton NHS Foundation Trust (Screening only)
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Karydis, Ioannis
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
SCOPE, NCT04079166 / 2018-002844-10: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study)

Recruiting
2
130
Europe
SCIB1 or iSCIB1+ DNA vaccine
Scancell Ltd, Scancell Ltd
Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
01/26
01/26
NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001

Terminated
2
1
Europe
Biological: ATL001
Achilles Therapeutics UK Limited
Melanoma, Advanced Non Small Cell Lung Cancer
10/23
10/23
HARE-40, NCT03418480: HPV Anti-CD40 RNA vaccinE

Completed
1/2
32
Europe
BNT113
University of Southampton, BioNTech SE
Human Papilloma Virus Related Carcinoma, Head and Neck Neoplasm, Cervical Neoplasm, Penile Neoplasms Malignant, Unknown Primary Tumors
11/23
01/24
NCT06380816: A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Recruiting
1/2
167
Europe
UCB4594
Cancer Research UK, UCB Biopharma SRL
Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms, Carcinoma, Renal Cell (Clear Cell Only), Esophageal Neoplasms, Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors), Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms
11/29
11/29
CRUKD/20/001, NCT04908111: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Suspended
1/2
103
Europe
ChAdOx1-MAGEA3-NYESO, MVA-MAGEA3, Standard of care treatment, MVA-NYESO
Cancer Research UK, Barinthus Biotherapeutics
Non-small Cell Lung Cancer (NSCLC), Esophageal Neoplasms
12/27
12/27
MOAT, NCT04830592: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
1
36
Europe
NG-641, Pembrolizumab
Akamis Bio
Squamous Cell Carcinoma of the Head and Neck
09/24
10/24

Download Options